FEG
ABBV icon

Fund Evaluation Group’s AbbVie ABBV Stock Holding History

Fund Evaluation Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,165
Closed -$1.25M – 22
2018
Q3 		$1.25M Sell
13,165
-2,746
-17% -$260K 0.21% 59
2018
Q2 		$1.47M Hold
15,911
– – 0.23% 47
2018
Q1 		$1.51M Hold
15,911
– – 0.17% 48
2017
Q4 		$1.54M Buy
+15,911
New +$1.5M 0.17% 51

Other funds holding ABBV

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fund Evaluation Group's ABBV Position: Q4 2018 in Review

Fund Evaluation Group sold out of AbbVie (ABBV) in Q4 2018, closing a stake of 13,165 shares — an estimated $1.25M sold.

Fund Evaluation Group first reported a position in ABBV in Q4 2017 and held it in 4 quarters. The position peaked at $1.54M in Q4 2017. 2,062 funds tracked by Wall St. Rank hold ABBV as of Q4 2018.

  • Fund Evaluation Group reported no remaining AbbVie position as of Q4 2018 after selling out during the quarter.
  • Fund Evaluation Group sold 13,165 AbbVie shares in Q4 2018, an estimated $1.25M.
  • Fund Evaluation Group first reported a position in AbbVie in Q4 2017 and held it in 4 quarters.
  • Fund Evaluation Group's AbbVie position peaked at $1.54M in Q4 2017.
  • 2,062 funds tracked by Wall St. Rank held AbbVie as of Q4 2018.

Based on Fund Evaluation Group's 13F filing for Q4 2018, filed 12 Feb 2019.